Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma

Kwan, Jennifer M.; Odanovic, Natalija; Arbune, Amit; Higgins, Angela; Henry, Mariana L.; Greif, Daniel M.; Foss, Francine M.; Baldassarre, Lauren A.

doi:10.1016/j.jaccas.2021.04.001

Cited by 6 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Newer immunotherapies may also increase risk of myocarditis, such as cellular therapies like CART and molecular inhibitors such as CCR4 antagonist, mogamulizumab, which is used to treat T cell lymphomas (26)(27)(28). However, evaluation of the earliest signs of immune cell infiltration in the myocarditis process is limited (Table 1; Figure 1).…”

Section: Introductionmentioning

confidence: 99%

Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data

Kwan

Oikonomou

Henry

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

Cancer mortality has improved due to earlier detection via screening, as well as due to novel cancer therapies such as tyrosine kinase inhibitors and immune checkpoint inhibitions. However, similarly to older cancer therapies such as anthracyclines, these therapies have also been documented to cause cardiotoxic events including cardiomyopathy, myocardial infarction, myocarditis, arrhythmia, hypertension, and thrombosis. Imaging modalities such as echocardiography and magnetic resonance imaging (MRI) are critical in monitoring and evaluating for cardiotoxicity from these treatments, as well as in providing information for the assessment of function and wall motion abnormalities. MRI also allows for additional tissue characterization using T1, T2, extracellular volume (ECV), and delayed gadolinium enhancement (DGE) assessment. Furthermore, emerging technologies may be able to assist with these efforts. Nuclear imaging using targeted radiotracers, some of which are already clinically used, may have more specificity and help provide information on the mechanisms of cardiotoxicity, including in anthracycline mediated cardiomyopathy and checkpoint inhibitor myocarditis. Hyperpolarized MRI may be used to evaluate the effects of oncologic therapy on cardiac metabolism. Lastly, artificial intelligence and big data of imaging modalities may help predict and detect early signs of cardiotoxicity and response to cardioprotective medications as well as provide insights on the added value of molecular imaging and correlations with cardiovascular outcomes. In this review, the current imaging modalities used to assess for cardiotoxicity from cancer treatments are discussed, in addition to ongoing research on targeted molecular radiotracers, hyperpolarized MRI, as well as the role of artificial intelligence (AI) and big data in imaging that would help improve the detection and prognostication of cancer-treatment cardiotoxicity.

show abstract

Section: Introductionmentioning

confidence: 99%